ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026)

ImmunityBio (IBRX) has 9 years of Other Operating Expenses data on file, last reported at -$236.6 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 455.69% year-over-year to -$236.6 million in Q1 2026; TTM through Mar 2026 was -$236.8 million, a 26708.54% decrease from a year earlier, with the FY2025 full-year figure at -$42.8 million, down 198.39% from the prior year.
• Other Operating Expenses for Q1 2026 stood at -$236.6 million, down from -$191000.0 in the prior quarter.
• Over the last five years, Other Operating Expenses for IBRX reached as high as $43.5 million in Q4 2024 and fell as low as -$236.6 million in Q1 2026.
• Historically, Other Operating Expenses has averaged -$30.2 million across 4 years, with a median of -$1.2 million in 2025.
• Across the five-year window, Other Operating Expenses soared 217.64% in 2024 and sank 455.69% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at -$37.0 million in 2023, then surged by 217.64% to $43.5 million in 2024, then plunged by 100.44% to -$191000.0 in 2025, then slumped by 123787.43% to -$236.6 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were -$236.6 million in Q1 2026, -$191000.0 in Q4 2025, and -$1.2 million in Q3 2025.